{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T16:50:31Z","timestamp":1790441431032,"version":"4.1.0"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,4,29]],"date-time":"2010-04-29T00:00:00Z","timestamp":1272499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In a Danish bi\u2010regional registry\u2010based study, we conducted an analysis of the incidence and clinical importance of secondary acute myeloid leukaemia (AML). In a total of 630 cases of AML, we found 157 (25%) cases of secondary AML. The secondary leukaemia arose from MDS (myelodysplastic syndrome) in 77 cases (49%), CMPD (chronic myeloproliferative disorder) in 43 cases (27%) and was therapy\u2010related AML (t\u2010AML) in 37 cases (24%). Median age at diagnosis of AML was 69\u2003yr in secondary cases when compared to 66\u2003yr in <jats:italic>de novo<\/jats:italic> cases (<jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.006). In univariate analyses, secondary AML was associated with an inferior complete remission (CR) rate (<jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.008) and poorer overall survival (OS, <jats:italic>P\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>0.003) whereas in complete remitters, disease\u2010free survival (DFS) of secondary cases was equal to that of <jats:italic>de novo<\/jats:italic> cases. Interestingly, in all further analyses of CR\u2010rates, OS and DFS, when correcting for the influence of age, cytogenetic abnormalities, performance status and leucocyte count (WBC), presence of secondary AML completely lost prognostic significance. We conclude that the presence of secondary AML does not <jats:italic>per se<\/jats:italic> convey an unfavourable prognosis and that patients with secondary AML should be offered the chance of benefiting from treatment according to current frontline AML protocols.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2010.01464.x","type":"journal-article","created":{"date-parts":[[2010,4,30]],"date-time":"2010-04-30T09:33:33Z","timestamp":1272620013000},"page":"217-226","source":"Crossref","is-referenced-by-count":50,"title":["Reasons for treating secondary AML as <i>de novo<\/i> AML"],"prefix":"10.1111","volume":"85","author":[{"given":"Lene Sofie Granfeldt","family":"\u00d8stg\u00e5rd","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eigil","family":"Kjeldsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mette Skov","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter De Nully","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjarne Bach","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knud","family":"Bendix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preben","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen Sch\u00f8ler","family":"Kristensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Maxwell","family":"N\u00f8rgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,12]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21260"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2006.12.449"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-162842"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3724"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.11.1637"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2006.10.006"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-172007"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-179341"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-192856"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24379"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07604.x"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07663.x"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2001.00553.x"},{"key":"e_1_2_8_15_2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1182\/blood.V32.4.507.507","article-title":"Arabinosyl cytosine: useful agent in the treatment of acute leukemia in adults","volume":"32","author":"Ellison RR","year":"1968","journal-title":"Blood"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-025627"},{"key":"e_1_2_8_18_2","volume-title":"ISCN 1995:an international system for human cytogenetic nomenclature (1995):recommendations of the International Standing Committee on Human Cytogenetic Nomenclature, Memphis, Tennessee, USA, October 9\u201013, 1994","author":"Mitelman F","year":"1995"},{"key":"e_1_2_8_19_2","volume-title":"ISCN 2005: an international system for human cytogenetic nomenclature (2005): recommendations of the International Standing Committee on Human Cytogenetic Nomenclature","author":"Shafer LG","year":"2005"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.7.2322"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.5.1312"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1976.tb03563.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-103-4-620"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1991.tb04444.x"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4165"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01684.x"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403187"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.99.301"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(87)92744-9"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24367"},{"key":"e_1_2_8_31_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.18.18","article-title":"A sensitive risk score for directing treatment in younger patients with AML","volume":"108","author":"Burnett A. K.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1982.tb02771.x"},{"key":"e_1_2_8_33_2","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2008"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-212530"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2010.01464.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2010.01464.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T21:35:54Z","timestamp":1698788154000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2010.01464.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,12]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1111\/j.1600-0609.2010.01464.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01464.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,12]]}}}